Thus, JAK inhibition likely prevents the activity of IL-4/IL-13 involved in the inflammation of atopic dermatitis as well as treats the inflammatory arthritis due to its effect on curbing the IL-23/17 pathway. Here, IL13 is linked to atopic eczema.